Coloplast Future Growth

Future criteria checks 2/6

Coloplast is forecast to grow earnings and revenue by 12.9% and 7.8% per annum respectively. EPS is expected to grow by 13.2% per annum. Return on equity is forecast to be 35.2% in 3 years.

Key information

12.9%

Earnings growth rate

13.2%

EPS growth rate

Medical Equipment earnings growth	17.1%
Revenue growth rate	7.8%
Future return on equity	35.2%
Analyst coverage	Good
Last updated	18 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

OTCPK:CLPB.Y - Analysts future estimates and past financials data (DKK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2027	34,526	7,522	7,366	8,630	14
9/30/2026	31,766	6,666	6,456	7,747	20
9/30/2025	29,282	5,746	5,508	6,700	18
9/30/2024	27,030	5,052	1,420	2,766	N/A
6/30/2024	26,303	4,967	1,313	2,599	N/A
3/31/2024	25,526	4,965	1,053	2,278	N/A
12/31/2023	25,001	4,868	4,285	5,527	N/A
9/30/2023	24,500	4,783	2,985	4,226	N/A
6/30/2023	24,333	4,784	3,226	4,485	N/A
3/31/2023	24,074	4,801	3,663	4,894	N/A
12/31/2022	23,515	4,626	3,246	4,455	N/A
9/30/2022	22,579	4,706	3,964	5,099	N/A
6/30/2022	21,620	4,781	3,894	4,913	N/A
3/31/2022	20,606	4,746	3,735	4,712	N/A
12/31/2021	19,857	4,896	4,272	5,209	N/A
9/30/2021	19,426	4,825	3,324	5,290	N/A
6/30/2021	18,916	4,561	3,102	5,023	N/A
3/31/2021	18,500	4,304	3,162	5,077	N/A
12/31/2020	18,570	4,241	3,003	4,941	N/A
9/30/2020	18,544	4,197	3,828	4,759	N/A
6/30/2020	18,572	3,949	3,876	4,842	N/A
3/31/2020	18,752	4,020	3,872	4,764	N/A
12/31/2019	18,330	3,974	3,833	4,615	N/A
9/30/2019	17,939	3,873	3,667	4,357	N/A
6/30/2019	17,555	4,119	3,599	4,161	N/A
3/31/2019	17,181	3,999	3,562	4,177	N/A
12/31/2018	16,815	3,896	3,522	4,126	N/A
9/30/2018	16,449	3,845	3,692	4,361	N/A
6/30/2018	16,195	3,816	N/A	4,370	N/A
3/31/2018	15,882	3,778	N/A	4,111	N/A
12/31/2017	15,728	3,791	N/A	4,004	N/A
9/30/2017	15,528	3,797	N/A	3,251	N/A
6/30/2017	15,287	3,211	N/A	2,994	N/A
3/31/2017	15,061	3,279	N/A	2,492	N/A
12/31/2016	14,780	3,264	N/A	2,653	N/A
9/30/2016	14,681	3,143	N/A	3,028	N/A
6/30/2016	14,563	1,297	N/A	3,081	N/A
3/31/2016	14,417	1,028	N/A	3,568	N/A
12/31/2015	14,264	927	N/A	3,320	N/A
9/30/2015	13,909	899	N/A	3,337	N/A
6/30/2015	13,502	3,162	N/A	3,119	N/A
3/31/2015	13,096	3,241	N/A	3,015	N/A
12/31/2014	12,666	2,407	N/A	3,193	N/A
9/30/2014	12,428	2,390	N/A	3,149	N/A
6/30/2014	12,184	2,298	N/A	3,177	N/A
3/31/2014	12,008	2,220	N/A	3,074	N/A
12/31/2013	11,833	2,874	N/A	3,270	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLPB.Y's forecast earnings growth (12.9% per year) is above the savings rate (2.6%).

Earnings vs Market: CLPB.Y's earnings (12.9% per year) are forecast to grow slower than the US market (15.3% per year).

High Growth Earnings: CLPB.Y's earnings are forecast to grow, but not significantly.

Revenue vs Market: CLPB.Y's revenue (7.8% per year) is forecast to grow slower than the US market (8.9% per year).

High Growth Revenue: CLPB.Y's revenue (7.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CLPB.Y's Return on Equity is forecast to be high in 3 years time (35.2%)

Coloplast Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies